rubella vaccine (The Wistar Institute)

The rubella vaccine (Wistar RA 27/3) is a live-attenuated viral vaccine derived from the RA 27/3 strain of the rubella virus, which was originally isolated and attenuated in human diploid cells at the Wistar Institute. While its primary global application is the prevention of rubella (German measles) and congenital rubella syndrome, it is also being investigated for novel therapeutic uses. Specifically, researchers at institutions such as Gentofte Hospital have explored the vaccine's potential as an immunomodulatory agent for chronic obstructive pulmonary disease (COPD). This research focuses on the concept of "trained immunity," where the live-attenuated virus induces epigenetic and functional reprogramming of innate immune cells, potentially reducing the frequency and severity of respiratory exacerbations in COPD patients by enhancing non-specific host defense mechanisms.

Brand names

Meruvax IIRudivaxErvevax

Other names

rubella vaccine (Wistar RA 27/3)rubella vaccine, livelive attenuated rubella vaccinerubella virus vaccine live